Table 1. Blood-brain barrier (BBB) penetration capabilities of EGFR- and ALK-TKIs in human.

TKIs	Penetration (CSF/blood)
EGFR-TKIs
Gefitinib	1.1% (43)
Erlotinib	2.8% (43)
Afatinib	1.7% (44)
Osimertinib
160 mg	16% (45)
80 mg	2.0% (46)
ALK-TKIs
Crizotinib	0.26% (47)
Ceritinib	No human data [animal model: 15% (48)]
Alectinib	No human data [animal model: 63–94% (49)]
Brigatinib	No human nor animal data
Lorlatinib	75% (50)

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; CSF, cerebrospinal fluid.